- Home
- REPX vs OMER Comparison
REPX vs OMER Comparison
Compare REPX & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REPX | OMER |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.6M | 772.8M |
| IPO Year | 2003 | 2008 |
Fundamental Metrics
Financial Performance| Metric | REPX | OMER |
|---|---|---|
| Price | $32.51 | $9.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $45.00 | $32.50 |
| AVG Volume (30 Days) | 250.9K | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | 78.17 | ★ 98.15 |
| EPS | N/A | ★ 0.62 |
| Revenue | $3,038,000.00 | ★ $29,868,000.00 |
| Revenue This Year | $33.41 | N/A |
| Revenue Next Year | $13.46 | $233.22 |
| P/E Ratio | ★ N/A | $14.97 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.08 | $3.34 |
| 52 Week High | $41.53 | $17.65 |
Technical Indicators
Market Signals| Indicator | REPX | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 40.66 |
| Support Level | $32.30 | $9.12 |
| Resistance Level | $36.85 | $11.88 |
| Average True Range (ATR) | 1.14 | 0.92 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 12.06 | 62.40 |
Price Performance
Historical ComparisonAbout REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations include: The Permian Basin is an oil and natural gas producing area located in West Texas.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.